Skip to main
INSM

Insmed (INSM) Stock Forecast & Price Target

Insmed (INSM) Analyst Ratings

Based on 18 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Insmed Inc. demonstrates a positive outlook due to the promising sales potential of its commercial product Brinsupri, which is projected to reach peak sales of approximately $5 billion or more, supported by strong endorsements from healthcare professionals. The company's reported double-digit year-over-year growth for Brinsupri, alongside Arikayce's 19% annual growth rate, indicates robust market penetration and effective chronic disease treatment strategies. Furthermore, the anticipated revenue growth positions Insmed on a path toward cash flow positivity, alleviating concerns regarding capital dilution for investors.

Bears say

Insmed Inc has recently experienced a pullback in its stock value following the disappointing results from the Phase 2b BiRCh study for brensocatib in chronic rhinosinusitis without nasal polyps, which has negatively impacted market expectations for its future clinical outcomes. Additionally, the company faces numerous risks that could hinder its growth, including potential deceleration in the launch of Brinsupri, the challenges associated with enrolling and completing clinical studies for its key products, and the lack of animal model validation for new indications. Moreover, Insmed's ongoing high cash burn rate, reported at $165-170 million, poses a significant concern as the company attempts to scale revenue, particularly as it prepares for upcoming international launches and the results of critical trials.

Insmed (INSM) has been analyzed by 18 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insmed (INSM) Forecast

Analysts have given Insmed (INSM) a Strong Buy based on their latest research and market trends.

According to 18 analysts, Insmed (INSM) has a Strong Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $208.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $208.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insmed (INSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.